|
Enzo Biochem, Inc. (ENZ) DCF Valuation
US | Healthcare | Medical - Diagnostics & Research | NYSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Enzo Biochem, Inc. (ENZ) Bundle
Discover the true potential of Enzo Biochem, Inc. (ENZ) with our professional-grade DCF Calculator! Adjust key assumptions, explore various scenarios, and examine how changes affect Enzo Biochem's valuation – all within a single Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.0 | 117.7 | 107.1 | 31.1 | 31.9 | 30.1 | 28.4 | 26.8 | 25.3 | 23.9 |
| Revenue Growth, % | 0 | 54.87 | -9.05 | -70.99 | 2.72 | -5.61 | -5.61 | -5.61 | -5.61 | -5.61 |
| EBITDA | -27.6 | 3.3 | -15.0 | -20.9 | -8.3 | -8.5 | -8.0 | -7.6 | -7.1 | -6.7 |
| EBITDA, % | -36.29 | 2.84 | -14.02 | -67.42 | -26.16 | -28.21 | -28.21 | -28.21 | -28.21 | -28.21 |
| Depreciation | 2.8 | 2.7 | 2.8 | 2.7 | 1.3 | 1.3 | 1.2 | 1.1 | 1.1 | 1.0 |
| Depreciation, % | 3.66 | 2.25 | 2.64 | 8.63 | 3.99 | 4.23 | 4.23 | 4.23 | 4.23 | 4.23 |
| EBIT | -30.4 | .7 | -17.8 | -23.6 | -9.6 | -9.8 | -9.2 | -8.7 | -8.2 | -7.8 |
| EBIT, % | -39.95 | 0.58778 | -16.66 | -76.05 | -30.15 | -32.44 | -32.44 | -32.44 | -32.44 | -32.44 |
| Total Cash | 47.9 | 43.5 | 21.6 | 82.4 | 52.4 | 19.3 | 18.2 | 17.2 | 16.2 | 15.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 9.1 | 10.2 | 4.8 | 4.8 | 4.0 | 3.2 | 3.0 | 2.8 | 2.7 | 2.5 |
| Account Receivables, % | 12.02 | 8.66 | 4.45 | 15.48 | 12.5 | 10.62 | 10.62 | 10.62 | 10.62 | 10.62 |
| Inventories | 7.8 | 12.7 | 15.4 | 7.9 | 6.8 | 5.0 | 4.7 | 4.4 | 4.2 | 3.9 |
| Inventories, % | 10.24 | 10.75 | 14.39 | 25.56 | 21.41 | 16.47 | 16.47 | 16.47 | 16.47 | 16.47 |
| Accounts Payable | 8.5 | 8.1 | 3.7 | 3.6 | 1.4 | 2.3 | 2.1 | 2.0 | 1.9 | 1.8 |
| Accounts Payable, % | 11.19 | 6.9 | 3.47 | 11.51 | 4.31 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 |
| Capital Expenditure | -2.2 | -4.4 | -3.5 | -2.8 | -.5 | -1.2 | -1.2 | -1.1 | -1.0 | -1.0 |
| Capital Expenditure, % | -2.85 | -3.77 | -3.24 | -8.89 | -1.71 | -4.09 | -4.09 | -4.09 | -4.09 | -4.09 |
| Tax Rate, % | -165.64 | -165.64 | -165.64 | -165.64 | -165.64 | -165.64 | -165.64 | -165.64 | -165.64 | -165.64 |
| EBITAT | -36.1 | .3 | -22.1 | 19.2 | -25.6 | -6.7 | -6.3 | -6.0 | -5.6 | -5.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -43.9 | -7.8 | -24.4 | 26.4 | -25.1 | -3.1 | -6.0 | -5.6 | -5.3 | -5.0 |
| WACC, % | 7.45 | 7.06 | 7.45 | 6.75 | 7.45 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -20.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5 | |||||||||
| Terminal Value | -98 | |||||||||
| Present Terminal Value | -69 | |||||||||
| Enterprise Value | -89 | |||||||||
| Net Debt | -49 | |||||||||
| Equity Value | -40 | |||||||||
| Diluted Shares Outstanding, MM | 51 | |||||||||
| Equity Value Per Share | -0.79 |
What You Will Get
- Real ENZ Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Enzo Biochem's future performance.
- User-Friendly Design: Designed for professionals while remaining easy for newcomers.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as revenue projections, gross margins, and R&D expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and various financial metrics.
- High-Precision Accuracy: Incorporates Enzo Biochem’s real-world financial data for credible valuation results.
- Effortless Scenario Analysis: Evaluate different hypotheses and analyze results with ease.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Download: Access the ready-to-use Excel file containing Enzo Biochem, Inc.'s (ENZ) financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate multiple projections and compare results instantly.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Enzo Biochem, Inc. (ENZ)?
- Accurate Data: Real Enzo Biochem financials provide dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Built-in calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants focused on biotech.
- User-Friendly: Easy-to-navigate design and step-by-step guidance cater to users of all experience levels.
Who Should Use This Product?
- Investors: Evaluate Enzo Biochem's valuation before making stock trades.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Enzo Biochem.
- Consultants: Provide expert valuation assessments for clients in the biotech sector.
- Students and Educators: Utilize current data to learn and teach valuation practices in biotechnology.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Enzo Biochem, Inc. (ENZ).
- Real-World Data: Enzo Biochem’s historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Visualizations such as charts and tables for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.